PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

Abstract The overexpression of Polo-like kinase 1 (PLK1) is associated with poor clinical outcomes in various malignancies, making it an attractive target for anticancer therapies. Although recent studies suggest PLK1’s involvement in homologous recombination (HR), the impact of its overexpression o...

Full description

Bibliographic Details
Main Authors: Sookhee Pae, Anna S. Sedukhina, Runa Sugiyama, Sarah J. Atanacio, Tatsuru Ohara, Masato Ishii, Kimino Minagawa, Romaan Akichjev, Fumie Go, Zayan Chandankeri, Zoran M. M. Janjetic, Eri Sato, Ayako Yamaura, Rei Meguro, Kishore Palanisamy, Ichiro Maeda, Osamu Takeuchi, Nao Suzuki, Kazuo Yudo, Juan A. Bernal, Ko Sato
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
PLK1
Overexpression
Cancer
Homologous recombination
PARP inhibition
Online Access:https://doi.org/10.1038/s41598-024-82724-w

Internet

https://doi.org/10.1038/s41598-024-82724-w

Similar Items